Apogee Therapeutics Stock Soars on Promising Trial Results for Atopic Dermatitis Drug

Overview of Apogee Therapeutics' Stock Movement#

Apogee Therapeutics (NASDAQ:APGE) saw its stock rise by 15% on Monday. This surge followed the release of encouraging data from the 52-week results of Part A of its Phase 2 APEX trial for zumilokibart (APG777), a treatment aimed at patients with moderate-to-severe atopic dermatitis, commonly known as eczema.

Trial Results Highlight Efficacy#

The trial results showed that patients maintained a significant response to treatment over 52 weeks, regardless of whether they received the drug every three months or every six months. Specifically, among patients who showed improvement by week 16, 75% of those on a quarterly schedule and 85% of those on a biannual schedule continued to meet the Eczema Area and Severity Index (EASI-75) criteria, which indicates a 75% reduction in eczema severity. Additionally, 86% and 78% of responders maintained low scores on the validated Investigator's Global Assessment (vIGA 0/1) with the two different dosing regimens.

Safety Profile and Side Effects#

The drug zumilokibart was generally well tolerated by participants, with a safety profile similar to other treatments in its category. The most frequently reported side effects included noninfective conjunctivitis (an eye condition), upper respiratory infections, and nasopharyngitis (inflammation of the nasal passages and throat).

Future Expectations#

Looking ahead, Apogee anticipates releasing data from Part B of the trial, which focuses on a 16-week induction phase, in the second quarter of 2026. This data is expected to pave the way for Phase 3 trials, which are planned to begin in the latter half of 2026, pending regulatory approval. If all goes well, the company is aiming for a potential commercial launch of zumilokibart in 2029. The findings will also be shared during a late-breaking presentation at the 2026 American Academy of Dermatology Annual Meeting on March 28.

Zumilokibart is designed to be administered less frequently than existing treatments for atopic dermatitis, which can require up to 26 injections each year.